ITM to Participate in Upcoming Investor Conferences

Garching / Munich, November 11, 2024 – ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor conferences. ITM’s Chief Executive Officer, Dr. Andrew Cavey, will participate in a virtual fireside chat at the William Blair Investor Conference. Dr. Cavey,

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Phase 1a results support further development of TX000045 for Group 2 Pulmonary Hypertension in HFpEF , based on favorable pharmacokinetic profile and impact on renal plasma flow TX45 showed a favorable safety profile, with no observed injection site reactions, immunogenicity, or detection of anti-drug antibodies RPF-based exposure-response model

EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis

EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy for individuals with liver disease Glasgow, Scotland – 11 November 2024. EnteroBiotix Limited , a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today